JP2007535520A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007535520A5 JP2007535520A5 JP2007510035A JP2007510035A JP2007535520A5 JP 2007535520 A5 JP2007535520 A5 JP 2007535520A5 JP 2007510035 A JP2007510035 A JP 2007510035A JP 2007510035 A JP2007510035 A JP 2007510035A JP 2007535520 A5 JP2007535520 A5 JP 2007535520A5
- Authority
- JP
- Japan
- Prior art keywords
- dimethoxy
- indole
- group
- methoxyphenyl
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 17
- 229910052757 nitrogen Inorganic materials 0.000 claims 13
- -1 hydroxyethyl group Chemical group 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 9
- 125000005842 heteroatom Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 4
- 125000003368 amide group Chemical group 0.000 claims 4
- 125000004185 ester group Chemical group 0.000 claims 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims 3
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims 3
- 125000004689 alkyl amino carbonyl alkyl group Chemical group 0.000 claims 3
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 3
- 125000004103 aminoalkyl group Chemical group 0.000 claims 3
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 claims 3
- 125000005100 aryl amino carbonyl group Chemical group 0.000 claims 3
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 3
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000002560 nitrile group Chemical group 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- LORDQUKLQXTKPZ-UHFFFAOYSA-N (5,6-dimethoxy-3-phenyl-1h-indol-2-yl)-morpholin-4-ylmethanone Chemical compound C=1C=CC=CC=1C=1C=2C=C(OC)C(OC)=CC=2NC=1C(=O)N1CCOCC1 LORDQUKLQXTKPZ-UHFFFAOYSA-N 0.000 claims 2
- VRDSTBRNIXSFGB-UHFFFAOYSA-N 1-(2-hydroxyethyl)-5,6-dimethoxy-3-(4-methoxyphenyl)indole-2-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1=C(C#N)N(CCO)C2=CC(OC)=C(OC)C=C12 VRDSTBRNIXSFGB-UHFFFAOYSA-N 0.000 claims 2
- JZQJPQWAGWVGEO-UHFFFAOYSA-N 1-(2-hydroxyethyl)-5,6-dimethoxy-3-phenylindole-2-carbonitrile Chemical compound N#CC=1N(CCO)C=2C=C(OC)C(OC)=CC=2C=1C1=CC=CC=C1 JZQJPQWAGWVGEO-UHFFFAOYSA-N 0.000 claims 2
- WRTBVIVYFUTKTG-UHFFFAOYSA-N 1-(3-hydroxypropyl)-5,6-dimethoxy-3-(4-methoxyphenyl)indole-2-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1=C(C#N)N(CCCO)C2=CC(OC)=C(OC)C=C12 WRTBVIVYFUTKTG-UHFFFAOYSA-N 0.000 claims 2
- PJKNOXRGHPXFBD-UHFFFAOYSA-N 1-[2-(dimethylamino)ethyl]-5,6-dimethoxy-3-(4-methoxyphenyl)indole-2-carbonitrile;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1C1=C(C#N)N(CCN(C)C)C2=CC(OC)=C(OC)C=C12 PJKNOXRGHPXFBD-UHFFFAOYSA-N 0.000 claims 2
- HOADMTXRGXJPFH-UHFFFAOYSA-N 1-[2-(dimethylamino)ethyl]-5,6-dimethoxy-3-phenylindole-2-carbonitrile;hydrochloride Chemical compound Cl.N#CC=1N(CCN(C)C)C=2C=C(OC)C(OC)=CC=2C=1C1=CC=CC=C1 HOADMTXRGXJPFH-UHFFFAOYSA-N 0.000 claims 2
- OQNIVCOOZCMYBB-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-5,6-dimethoxy-3-(4-methoxyphenyl)indole-2-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1=C(C#N)N(CCCN(C)C)C2=CC(OC)=C(OC)C=C12 OQNIVCOOZCMYBB-UHFFFAOYSA-N 0.000 claims 2
- OEKNNPPXKIXUBZ-UHFFFAOYSA-N 1-[7,8-dimethoxy-10-(4-methoxyphenyl)-3,4-dihydro-1h-pyrazino[1,2-a]indol-2-yl]ethanone Chemical compound C1=CC(OC)=CC=C1C(C1=CC(OC)=C(OC)C=C11)=C2N1CCN(C(C)=O)C2 OEKNNPPXKIXUBZ-UHFFFAOYSA-N 0.000 claims 2
- KPJCTLDXBGZBOO-UHFFFAOYSA-N 2-(5,6-dimethoxy-3-phenyl-1h-indol-2-yl)-4,5-dihydro-1,3-oxazole Chemical compound C=1C=CC=CC=1C=1C=2C=C(OC)C(OC)=CC=2NC=1C1=NCCO1 KPJCTLDXBGZBOO-UHFFFAOYSA-N 0.000 claims 2
- PKQALAZFZVHRNK-UHFFFAOYSA-N 2-[5,6-dimethoxy-3-(4-methoxyphenyl)-1H-indol-2-yl]-5-methyl-1,3,4-oxadiazole Chemical compound C1=CC(OC)=CC=C1C1=C(C=2OC(C)=NN=2)NC2=CC(OC)=C(OC)C=C12 PKQALAZFZVHRNK-UHFFFAOYSA-N 0.000 claims 2
- DAACTXYLMQNTLO-UHFFFAOYSA-N 2-[5,6-dimethoxy-3-(4-methoxyphenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)indol-1-yl]-n,n-dimethylethanamine Chemical compound C1=CC(OC)=CC=C1C(C1=CC(OC)=C(OC)C=C1N1CCN(C)C)=C1C1=NN=C(C)O1 DAACTXYLMQNTLO-UHFFFAOYSA-N 0.000 claims 2
- LENZMQGXLVYFBT-UHFFFAOYSA-N 2-[5,6-dimethoxy-3-(4-methoxyphenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)indol-1-yl]ethanol Chemical compound C1=CC(OC)=CC=C1C(C1=CC(OC)=C(OC)C=C1N1CCO)=C1C1=NN=C(C)O1 LENZMQGXLVYFBT-UHFFFAOYSA-N 0.000 claims 2
- XSTFNIJEXSUSAR-UHFFFAOYSA-N 2-indol-1-yl-3H-oxadiazole Chemical compound O1N(NC=C1)N1C=CC2=CC=CC=C12 XSTFNIJEXSUSAR-UHFFFAOYSA-N 0.000 claims 2
- GOMKJZNSPXZXQI-UHFFFAOYSA-N 5,6-dimethoxy-3-(4-methoxyphenyl)-1-(2-morpholin-4-ylethyl)indole-2-carbonitrile;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1C(C1=CC(OC)=C(OC)C=C11)=C(C#N)N1CCN1CCOCC1 GOMKJZNSPXZXQI-UHFFFAOYSA-N 0.000 claims 2
- TZAJMZPWHHOSDR-UHFFFAOYSA-N 5,6-dimethoxy-3-(4-methoxyphenyl)-1-(2-pyrrolidin-1-ylethyl)indole-2-carbonitrile;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1C(C1=CC(OC)=C(OC)C=C11)=C(C#N)N1CCN1CCCC1 TZAJMZPWHHOSDR-UHFFFAOYSA-N 0.000 claims 2
- MJIIFQSGKWOMJQ-UHFFFAOYSA-N 5,6-dimethoxy-3-(4-methoxyphenyl)-1-[2-(4-methylpiperazin-1-yl)ethyl]indole-2-carbonitrile;dihydrochloride Chemical compound Cl.Cl.C1=CC(OC)=CC=C1C(C1=CC(OC)=C(OC)C=C11)=C(C#N)N1CCN1CCN(C)CC1 MJIIFQSGKWOMJQ-UHFFFAOYSA-N 0.000 claims 2
- GDJLZLJTRKUMEJ-UHFFFAOYSA-N 5,6-dimethoxy-3-(4-methoxyphenyl)-1h-indole-2-carbonitrile Chemical compound C1=CC(OC)=CC=C1C1=C(C#N)NC2=CC(OC)=C(OC)C=C12 GDJLZLJTRKUMEJ-UHFFFAOYSA-N 0.000 claims 2
- KMTHJDFUUPIDOC-UHFFFAOYSA-N 5,6-dimethoxy-3-(4-methoxyphenyl)-2-(1H-1,2,4-triazol-5-yl)-1H-indole Chemical compound C1=CC(OC)=CC=C1C1=C(C=2NN=CN=2)NC2=CC(OC)=C(OC)C=C12 KMTHJDFUUPIDOC-UHFFFAOYSA-N 0.000 claims 2
- TUYBZVBOPJMOCY-UHFFFAOYSA-N 5,6-dimethoxy-3-(4-methoxyphenyl)-2-(2H-tetrazol-5-yl)-1H-indole Chemical compound C1=CC(OC)=CC=C1C1=C(C=2NN=NN=2)NC2=CC(OC)=C(OC)C=C12 TUYBZVBOPJMOCY-UHFFFAOYSA-N 0.000 claims 2
- SRLBTZMZYZDXTF-UHFFFAOYSA-N 5,6-dimethoxy-3-phenyl-1-propylindole-2-carbonitrile Chemical compound C12=CC(OC)=C(OC)C=C2N(CCC)C(C#N)=C1C1=CC=CC=C1 SRLBTZMZYZDXTF-UHFFFAOYSA-N 0.000 claims 2
- MOUMUITYHSHJGQ-UHFFFAOYSA-N 5,6-dimethoxy-3-phenyl-1h-indole-2-carbonitrile Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(C#N)=C1C1=CC=CC=C1 MOUMUITYHSHJGQ-UHFFFAOYSA-N 0.000 claims 2
- ILIFMLLAFSCLJM-UHFFFAOYSA-N 5,6-dimethoxy-3-phenyl-2-(1H-1,2,4-triazol-5-yl)-1H-indole Chemical compound C=1C=CC=CC=1C=1C=2C=C(OC)C(OC)=CC=2NC=1C1=NN=CN1 ILIFMLLAFSCLJM-UHFFFAOYSA-N 0.000 claims 2
- FLFYNTHFAXXVOE-UHFFFAOYSA-N 7,8-dimethoxy-10-(4-methoxyphenyl)-1,2,3,4-tetrahydropyrazino[1,2-a]indole;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1C(C1=CC(OC)=C(OC)C=C11)=C2N1CCNC2 FLFYNTHFAXXVOE-UHFFFAOYSA-N 0.000 claims 2
- OSMBPVBPUKXOQW-UHFFFAOYSA-N 7,8-dimethoxy-10-(4-methoxyphenyl)-2,4-dihydro-1h-pyrazino[1,2-a]indol-3-one Chemical compound C1=CC(OC)=CC=C1C(C1=CC(OC)=C(OC)C=C11)=C2N1CC(=O)NC2 OSMBPVBPUKXOQW-UHFFFAOYSA-N 0.000 claims 2
- JQDPWKYSIKYUBZ-UHFFFAOYSA-N 7,8-dimethoxy-10-(4-methoxyphenyl)-2-(4-methylphenyl)sulfonyl-3,4-dihydro-1h-pyrazino[1,2-a]indole Chemical compound C1=CC(OC)=CC=C1C(C1=CC(OC)=C(OC)C=C11)=C2N1CCN(S(=O)(=O)C=1C=CC(C)=CC=1)C2 JQDPWKYSIKYUBZ-UHFFFAOYSA-N 0.000 claims 2
- NBKOJGYFPMCRLC-UHFFFAOYSA-N 7,8-dimethoxy-10-(4-methoxyphenyl)-2-methyl-3,4-dihydro-1h-pyrazino[1,2-a]indole;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1C(C1=CC(OC)=C(OC)C=C11)=C2N1CCN(C)C2 NBKOJGYFPMCRLC-UHFFFAOYSA-N 0.000 claims 2
- CCVOMIOATVNKPF-UHFFFAOYSA-N 7,8-dimethoxy-10-(4-methoxyphenyl)-2-methylsulfonyl-3,4-dihydro-1h-pyrazino[1,2-a]indole Chemical compound C1=CC(OC)=CC=C1C(C1=CC(OC)=C(OC)C=C11)=C2N1CCN(S(C)(=O)=O)C2 CCVOMIOATVNKPF-UHFFFAOYSA-N 0.000 claims 2
- WKFLURXVXBOZPW-UHFFFAOYSA-N 7,8-dimethoxy-10-(4-methoxyphenyl)-2-propan-2-yl-3,4-dihydro-1h-pyrazino[1,2-a]indole;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1C(C1=CC(OC)=C(OC)C=C11)=C2N1CCN(C(C)C)C2 WKFLURXVXBOZPW-UHFFFAOYSA-N 0.000 claims 2
- CROSEMLHHCGFEG-UHFFFAOYSA-N 7,8-dimethoxy-10-(4-methoxyphenyl)-2-propan-2-ylsulfonyl-3,4-dihydro-1h-pyrazino[1,2-a]indole Chemical compound C1=CC(OC)=CC=C1C(C1=CC(OC)=C(OC)C=C11)=C2N1CCN(S(=O)(=O)C(C)C)C2 CROSEMLHHCGFEG-UHFFFAOYSA-N 0.000 claims 2
- UCNZPMHYGWAUKW-UHFFFAOYSA-N 7,8-dimethoxy-10-(4-methoxyphenyl)-3,4-dihydro-1h-[1,4]oxazino[4,3-a]indole Chemical compound C1=CC(OC)=CC=C1C(C1=CC(OC)=C(OC)C=C11)=C2N1CCOC2 UCNZPMHYGWAUKW-UHFFFAOYSA-N 0.000 claims 2
- KTROSXPIJJZINL-UHFFFAOYSA-N 7,8-dimethoxy-10-(4-methoxyphenyl)-3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one Chemical compound C1=CC(OC)=CC=C1C(C1=CC(OC)=C(OC)C=C11)=C2N1CCNC2=O KTROSXPIJJZINL-UHFFFAOYSA-N 0.000 claims 2
- KAAZZEBFTFXGJQ-UHFFFAOYSA-N 7,8-dimethoxy-10-(4-methoxyphenyl)-n-methyl-3,4-dihydro-1h-pyrazino[1,2-a]indole-2-carboxamide Chemical compound C1N(C(=O)NC)CCN(C2=CC(OC)=C(OC)C=C22)C1=C2C1=CC=C(OC)C=C1 KAAZZEBFTFXGJQ-UHFFFAOYSA-N 0.000 claims 2
- RSWFMUPFLONLLK-UHFFFAOYSA-N 7,8-dimethoxy-10-phenyl-1,2,3,4-tetrahydropyrazino[1,2-a]indole;hydrochloride Chemical compound Cl.C=12CNCCN2C=2C=C(OC)C(OC)=CC=2C=1C1=CC=CC=C1 RSWFMUPFLONLLK-UHFFFAOYSA-N 0.000 claims 2
- LRXXWNGXTYIZBE-UHFFFAOYSA-N 7,8-dimethoxy-10-phenyl-3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one Chemical compound C=12C(=O)NCCN2C=2C=C(OC)C(OC)=CC=2C=1C1=CC=CC=C1 LRXXWNGXTYIZBE-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 2
- KVDJLKCCIRQYTG-UHFFFAOYSA-N methyl 1-(2-amino-2-oxoethyl)-5,6-dimethoxy-3-(4-methoxyphenyl)indole-2-carboxylate Chemical compound C12=CC(OC)=C(OC)C=C2N(CC(N)=O)C(C(=O)OC)=C1C1=CC=C(OC)C=C1 KVDJLKCCIRQYTG-UHFFFAOYSA-N 0.000 claims 2
- YFEYHWKORAOCAF-UHFFFAOYSA-N methyl 1-(2-aminoethyl)-5,6-dimethoxy-3-(4-methoxyphenyl)indole-2-carboxylate;hydrochloride Chemical compound Cl.C12=CC(OC)=C(OC)C=C2N(CCN)C(C(=O)OC)=C1C1=CC=C(OC)C=C1 YFEYHWKORAOCAF-UHFFFAOYSA-N 0.000 claims 2
- YGLHNIWIMOFCRJ-UHFFFAOYSA-N methyl 1-(2-hydroxyethyl)-5,6-dimethoxy-3-(4-methoxyphenyl)indole-2-carboxylate Chemical compound C12=CC(OC)=C(OC)C=C2N(CCO)C(C(=O)OC)=C1C1=CC=C(OC)C=C1 YGLHNIWIMOFCRJ-UHFFFAOYSA-N 0.000 claims 2
- FCBGCWBDDDUSLI-UHFFFAOYSA-N methyl 1-(3-hydroxypropyl)-5,6-dimethoxy-3-(4-methoxyphenyl)indole-2-carboxylate Chemical compound C12=CC(OC)=C(OC)C=C2N(CCCO)C(C(=O)OC)=C1C1=CC=C(OC)C=C1 FCBGCWBDDDUSLI-UHFFFAOYSA-N 0.000 claims 2
- KXFOXHRUJNNQAQ-UHFFFAOYSA-N methyl 1-(cyanomethyl)-5,6-dimethoxy-3-(4-methoxyphenyl)indole-2-carboxylate Chemical compound C12=CC(OC)=C(OC)C=C2N(CC#N)C(C(=O)OC)=C1C1=CC=C(OC)C=C1 KXFOXHRUJNNQAQ-UHFFFAOYSA-N 0.000 claims 2
- QOPYGQMLZKFFPO-UHFFFAOYSA-N methyl 1-[2-(dimethylamino)-2-oxoethyl]-5,6-dimethoxy-3-(4-methoxyphenyl)indole-2-carboxylate Chemical compound C12=CC(OC)=C(OC)C=C2N(CC(=O)N(C)C)C(C(=O)OC)=C1C1=CC=C(OC)C=C1 QOPYGQMLZKFFPO-UHFFFAOYSA-N 0.000 claims 2
- KSBIKQMUESKOMW-UHFFFAOYSA-N methyl 1-[2-(dimethylamino)ethyl]-5,6-dimethoxy-3-(4-methoxyphenyl)indole-2-carboxylate;hydrochloride Chemical compound Cl.C12=CC(OC)=C(OC)C=C2N(CCN(C)C)C(C(=O)OC)=C1C1=CC=C(OC)C=C1 KSBIKQMUESKOMW-UHFFFAOYSA-N 0.000 claims 2
- KPDNFZPAGRGBCO-UHFFFAOYSA-N methyl 1-[3-(dimethylamino)propyl]-5,6-dimethoxy-3-(4-methoxyphenyl)indole-2-carboxylate;hydrochloride Chemical compound Cl.C12=CC(OC)=C(OC)C=C2N(CCCN(C)C)C(C(=O)OC)=C1C1=CC=C(OC)C=C1 KPDNFZPAGRGBCO-UHFFFAOYSA-N 0.000 claims 2
- PIFNRGUHVQRYKQ-UHFFFAOYSA-N methyl 1-benzyl-5,6-dimethoxy-3-(4-methoxyphenyl)indole-2-carboxylate Chemical compound C12=CC(OC)=C(OC)C=C2N(CC=2C=CC=CC=2)C(C(=O)OC)=C1C1=CC=C(OC)C=C1 PIFNRGUHVQRYKQ-UHFFFAOYSA-N 0.000 claims 2
- RZACXYWBWBAXKO-UHFFFAOYSA-N methyl 5,6-dimethoxy-1-(2-methoxy-2-oxoethyl)-3-(4-methoxyphenyl)indole-2-carboxylate Chemical compound C12=CC(OC)=C(OC)C=C2N(CC(=O)OC)C(C(=O)OC)=C1C1=CC=C(OC)C=C1 RZACXYWBWBAXKO-UHFFFAOYSA-N 0.000 claims 2
- FHLHBJCFQGAUSD-UHFFFAOYSA-N methyl 5,6-dimethoxy-1-(2-methoxyethyl)-3-(4-methoxyphenyl)indole-2-carboxylate Chemical compound C12=CC(OC)=C(OC)C=C2N(CCOC)C(C(=O)OC)=C1C1=CC=C(OC)C=C1 FHLHBJCFQGAUSD-UHFFFAOYSA-N 0.000 claims 2
- ZLZSBGQEXCNVHA-UHFFFAOYSA-N methyl 5,6-dimethoxy-3-(4-methoxyphenyl)-1-(2-morpholin-4-ylethyl)indole-2-carboxylate;hydrochloride Chemical compound Cl.C12=CC(OC)=C(OC)C=C2N(CCN2CCOCC2)C(C(=O)OC)=C1C1=CC=C(OC)C=C1 ZLZSBGQEXCNVHA-UHFFFAOYSA-N 0.000 claims 2
- JQORPSVTMQXKID-UHFFFAOYSA-N methyl 5,6-dimethoxy-3-(4-methoxyphenyl)-1-(2-pyrrolidin-1-ylethyl)indole-2-carboxylate;hydrochloride Chemical compound Cl.C12=CC(OC)=C(OC)C=C2N(CCN2CCCC2)C(C(=O)OC)=C1C1=CC=C(OC)C=C1 JQORPSVTMQXKID-UHFFFAOYSA-N 0.000 claims 2
- ORFITJDJBBTDQZ-UHFFFAOYSA-N methyl 5,6-dimethoxy-3-(4-methoxyphenyl)-1-[2-(4-methylpiperazin-1-yl)ethyl]indole-2-carboxylate;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2N(CCN2CCN(C)CC2)C(C(=O)OC)=C1C1=CC=C(OC)C=C1 ORFITJDJBBTDQZ-UHFFFAOYSA-N 0.000 claims 2
- MXCOSTUYBATMQM-UHFFFAOYSA-N methyl 5,6-dimethoxy-3-(4-methoxyphenyl)-1-[2-(methylamino)-2-oxoethyl]indole-2-carboxylate Chemical compound C12=CC(OC)=C(OC)C=C2N(CC(=O)NC)C(C(=O)OC)=C1C1=CC=C(OC)C=C1 MXCOSTUYBATMQM-UHFFFAOYSA-N 0.000 claims 2
- UAZIEQFZSVQFEC-UHFFFAOYSA-N n-[[5,6-dimethoxy-3-(4-methoxyphenyl)-1h-indol-2-yl]methyl]acetamide Chemical compound C1=CC(OC)=CC=C1C1=C(CNC(C)=O)NC2=CC(OC)=C(OC)C=C12 UAZIEQFZSVQFEC-UHFFFAOYSA-N 0.000 claims 2
- AEIDURNZWCNQIM-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrazino[1,2-a]indole Chemical compound C1=CC=C2N3CCNCC3=CC2=C1 AEIDURNZWCNQIM-UHFFFAOYSA-N 0.000 claims 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 1
- HVZAFNRIZAKUQS-UHFFFAOYSA-N 3,4-dihydro-1h-[1,4]oxazino[4,3-a]indole Chemical compound C1=CC=C2N3CCOCC3=CC2=C1 HVZAFNRIZAKUQS-UHFFFAOYSA-N 0.000 claims 1
- KRRWBFJXTNMYOZ-UHFFFAOYSA-N 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one Chemical compound C1=CC=C2N3CCNC(=O)C3=CC2=C1 KRRWBFJXTNMYOZ-UHFFFAOYSA-N 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- TWLJBVBWKQFUQD-UHFFFAOYSA-N 5,6-dimethoxy-3-(4-methoxyphenyl)-1h-indole-2-carboxamide Chemical compound C1=CC(OC)=CC=C1C1=C(C(N)=O)NC2=CC(OC)=C(OC)C=C12 TWLJBVBWKQFUQD-UHFFFAOYSA-N 0.000 claims 1
- LRJRYRFBXQZDRU-UHFFFAOYSA-N 5,6-dimethoxy-3-phenyl-1h-indole-2-carboxamide Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(C(N)=O)=C1C1=CC=CC=C1 LRJRYRFBXQZDRU-UHFFFAOYSA-N 0.000 claims 1
- GEDABJRCUZMZJI-UHFFFAOYSA-N 5,6-dimethoxy-n,n-dimethyl-3-phenyl-1h-indole-2-carboxamide Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(C(=O)N(C)C)=C1C1=CC=CC=C1 GEDABJRCUZMZJI-UHFFFAOYSA-N 0.000 claims 1
- PNBJSBFFPBYBOR-UHFFFAOYSA-N 5,6-dimethoxy-n-methyl-3-phenyl-1h-indole-2-carboxamide Chemical compound CNC(=O)C=1NC2=CC(OC)=C(OC)C=C2C=1C1=CC=CC=C1 PNBJSBFFPBYBOR-UHFFFAOYSA-N 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 239000002257 antimetastatic agent Substances 0.000 claims 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 208000025997 central nervous system neoplasm Diseases 0.000 claims 1
- 210000002249 digestive system Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 1
- JPDIBWCNNQFQEP-UHFFFAOYSA-N ethyl 3-phenyl-1h-indole-2-carboxylate Chemical compound CCOC(=O)C=1NC2=CC=CC=C2C=1C1=CC=CC=C1 JPDIBWCNNQFQEP-UHFFFAOYSA-N 0.000 claims 1
- PVKRDBCQHZFPAX-UHFFFAOYSA-N ethyl 5,6-dimethoxy-3-phenyl-1h-indole-2-carboxylate Chemical compound CCOC(=O)C=1NC2=CC(OC)=C(OC)C=C2C=1C1=CC=CC=C1 PVKRDBCQHZFPAX-UHFFFAOYSA-N 0.000 claims 1
- FSLOLRKVZPTMHC-UHFFFAOYSA-N ethyl 5-chloro-3-phenyl-1h-indole-2-carboxylate Chemical compound CCOC(=O)C=1NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 FSLOLRKVZPTMHC-UHFFFAOYSA-N 0.000 claims 1
- XBBONQKRNZIXTH-UHFFFAOYSA-N ethyl 5-fluoro-3-phenyl-1h-indole-2-carboxylate Chemical compound CCOC(=O)C=1NC2=CC=C(F)C=C2C=1C1=CC=CC=C1 XBBONQKRNZIXTH-UHFFFAOYSA-N 0.000 claims 1
- LLBDOBISQBECLH-UHFFFAOYSA-N ethyl 5-hydroxy-3-phenyl-1h-indole-2-carboxylate Chemical compound CCOC(=O)C=1NC2=CC=C(O)C=C2C=1C1=CC=CC=C1 LLBDOBISQBECLH-UHFFFAOYSA-N 0.000 claims 1
- DOIDLAVLCKENCM-UHFFFAOYSA-N ethyl 5-methoxy-3-phenyl-1h-indole-2-carboxylate Chemical compound CCOC(=O)C=1NC2=CC=C(OC)C=C2C=1C1=CC=CC=C1 DOIDLAVLCKENCM-UHFFFAOYSA-N 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000007902 hard capsule Substances 0.000 claims 1
- 229940041682 inhalant solution Drugs 0.000 claims 1
- 229940102223 injectable solution Drugs 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- CHXQLKJUJCVMTK-UHFFFAOYSA-N methyl 3-(2-chlorophenyl)-5,6-dimethoxy-1h-indole-2-carboxylate Chemical compound COC(=O)C=1NC2=CC(OC)=C(OC)C=C2C=1C1=CC=CC=C1Cl CHXQLKJUJCVMTK-UHFFFAOYSA-N 0.000 claims 1
- KFZGADIVBKXPKF-UHFFFAOYSA-N methyl 3-(3,4-dimethoxyphenyl)-5,6-dimethoxy-1h-indole-2-carboxylate Chemical compound COC(=O)C=1NC2=CC(OC)=C(OC)C=C2C=1C1=CC=C(OC)C(OC)=C1 KFZGADIVBKXPKF-UHFFFAOYSA-N 0.000 claims 1
- NQCOHWFQRSVAHH-UHFFFAOYSA-N methyl 3-(3-chlorophenyl)-5,6-dimethoxy-1h-indole-2-carboxylate Chemical compound COC(=O)C=1NC2=CC(OC)=C(OC)C=C2C=1C1=CC=CC(Cl)=C1 NQCOHWFQRSVAHH-UHFFFAOYSA-N 0.000 claims 1
- HLNDMBOAQWCCGQ-UHFFFAOYSA-N methyl 3-(4-chlorophenyl)-5,6-dimethoxy-1h-indole-2-carboxylate Chemical compound COC(=O)C=1NC2=CC(OC)=C(OC)C=C2C=1C1=CC=C(Cl)C=C1 HLNDMBOAQWCCGQ-UHFFFAOYSA-N 0.000 claims 1
- RWBHWSUJSFZICA-UHFFFAOYSA-N methyl 3-(4-fluorophenyl)-5,6-dimethoxy-1h-indole-2-carboxylate Chemical compound COC(=O)C=1NC2=CC(OC)=C(OC)C=C2C=1C1=CC=C(F)C=C1 RWBHWSUJSFZICA-UHFFFAOYSA-N 0.000 claims 1
- AZSXHQAYXGZVCY-UHFFFAOYSA-N methyl 3-(4-methoxyphenyl)-1h-indole-2-carboxylate Chemical compound COC(=O)C=1NC2=CC=CC=C2C=1C1=CC=C(OC)C=C1 AZSXHQAYXGZVCY-UHFFFAOYSA-N 0.000 claims 1
- UCOFWTALVXAQCE-UHFFFAOYSA-N methyl 5,6-dimethoxy-3-(4-methoxyphenyl)-1-propylindole-2-carboxylate Chemical compound C12=CC(OC)=C(OC)C=C2N(CCC)C(C(=O)OC)=C1C1=CC=C(OC)C=C1 UCOFWTALVXAQCE-UHFFFAOYSA-N 0.000 claims 1
- IYNGKMZSLRPOQX-UHFFFAOYSA-N methyl 5,6-dimethoxy-3-(4-methoxyphenyl)-1h-indole-2-carboxylate Chemical compound COC(=O)C=1NC2=CC(OC)=C(OC)C=C2C=1C1=CC=C(OC)C=C1 IYNGKMZSLRPOQX-UHFFFAOYSA-N 0.000 claims 1
- PVFSUKCFXLNXNT-UHFFFAOYSA-N methyl 5,6-dimethoxy-3-(4-methylphenyl)-1h-indole-2-carboxylate Chemical compound COC(=O)C=1NC2=CC(OC)=C(OC)C=C2C=1C1=CC=C(C)C=C1 PVFSUKCFXLNXNT-UHFFFAOYSA-N 0.000 claims 1
- LFWJSDFFEOXJSR-UHFFFAOYSA-N methyl 5,6-dimethoxy-3-[4-(trifluoromethyl)phenyl]-1h-indole-2-carboxylate Chemical compound COC(=O)C=1NC2=CC(OC)=C(OC)C=C2C=1C1=CC=C(C(F)(F)F)C=C1 LFWJSDFFEOXJSR-UHFFFAOYSA-N 0.000 claims 1
- DZYDQRZYZTVOGA-UHFFFAOYSA-N methyl 5,6-dimethoxy-3-phenyl-1h-indole-2-carboxylate Chemical compound COC(=O)C=1NC2=CC(OC)=C(OC)C=C2C=1C1=CC=CC=C1 DZYDQRZYZTVOGA-UHFFFAOYSA-N 0.000 claims 1
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims 1
- 239000003094 microcapsule Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 150000003058 platinum compounds Chemical class 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000002534 radiation-sensitizing agent Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 239000007901 soft capsule Substances 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 208000029584 urinary system neoplasm Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000874A ITMI20040874A1 (it) | 2004-04-30 | 2004-04-30 | Derivati indolici ed azaindolici con azione antitumorale |
| PCT/EP2005/051908 WO2005105213A2 (en) | 2004-04-30 | 2005-04-27 | Indole and azaindole derivatives with antitumor action |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007535520A JP2007535520A (ja) | 2007-12-06 |
| JP2007535520A5 true JP2007535520A5 (enExample) | 2008-06-19 |
Family
ID=34968098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007510035A Pending JP2007535520A (ja) | 2004-04-30 | 2005-04-27 | 抗腫瘍作用を有するインドール及びアザインドール誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070248672A1 (enExample) |
| EP (1) | EP1750687A2 (enExample) |
| JP (1) | JP2007535520A (enExample) |
| AU (1) | AU2005237788A1 (enExample) |
| CA (1) | CA2564249A1 (enExample) |
| IT (1) | ITMI20040874A1 (enExample) |
| WO (1) | WO2005105213A2 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005095400A1 (en) | 2004-03-30 | 2005-10-13 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of jak and other protein kinases |
| EP1779848A1 (en) * | 2005-10-28 | 2007-05-02 | Nikem Research S.R.L. | V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases |
| EP1779849A1 (en) * | 2005-10-28 | 2007-05-02 | Nikem Research S.R.L. | V-ATPase inhibitors for the treatment of septic shock |
| JP2010503677A (ja) | 2006-09-15 | 2010-02-04 | シェーリング コーポレイション | 脂質代謝の障害を治療するためのアゼチジノン誘導体 |
| CN101678022A (zh) | 2006-12-21 | 2010-03-24 | 弗特克斯药品有限公司 | 可用作蛋白激酶抑制剂的5-氰基-4-(吡咯并[2,3b]吡啶-3-基)嘧啶衍生物 |
| US20100183658A1 (en) * | 2007-03-30 | 2010-07-22 | The Brigham And Women's Hospital, Inc. | Novel Compounds for Enhancing MHC Class II Therapies |
| CA2951295C (en) * | 2007-04-16 | 2020-04-28 | Abbvie Inc. | 7-nonsubstituted indole mcl-1 inhibitors |
| WO2010144611A2 (en) * | 2009-06-10 | 2010-12-16 | 3-V Biosciences, Inc. | Antivirals that target transporters, carriers, and ion channels |
| AU2010262905B2 (en) | 2009-06-17 | 2015-04-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| JP5687704B2 (ja) * | 2009-10-07 | 2015-03-18 | カロ バイオ アクチェブラーグ | 新規エストロゲン受容体リガンド |
| HRP20161092T1 (hr) | 2010-10-25 | 2016-10-21 | G1 Therapeutics, Inc. | Cdk inhibitori |
| US8691830B2 (en) | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
| KR20140014110A (ko) | 2010-12-16 | 2014-02-05 | 버텍스 파마슈티칼스 인코포레이티드 | 인플루엔자 바이러스 복제의 억제제 |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| GB201113538D0 (en) | 2011-08-04 | 2011-09-21 | Karobio Ab | Novel estrogen receptor ligands |
| AU2013232066B2 (en) | 2012-03-16 | 2017-07-06 | Vitae Pharmaceuticals, Inc. | Liver X receptor modulators |
| LT2825542T (lt) | 2012-03-16 | 2016-12-27 | Vitae Pharmaceuticals, Inc. | Kepenų x receptoriaus moduliatoriai |
| CA2868966C (en) | 2012-03-29 | 2021-01-26 | Francis Xavier Tavares | Lactam kinase inhibitors |
| ES2734479T3 (es) * | 2012-09-21 | 2019-12-10 | Vivolux Ab | Medios y métodos para tratar tumores sólidos |
| WO2014144326A1 (en) | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Transient protection of normal cells during chemotherapy |
| CN105407723A (zh) | 2013-03-15 | 2016-03-16 | G1治疗公司 | 高效的抗赘生剂和抗增生剂 |
| MA38569A1 (fr) * | 2013-04-23 | 2017-03-31 | Esteve Labor Dr | Composés pyrazino[1,2-a]indole, leur préparation et utilisation dans des médicaments |
| ES2741444T3 (es) | 2013-11-13 | 2020-02-11 | Vertex Pharma | Inhibidores de la replicación de virus de la gripe |
| EP3068782B1 (en) | 2013-11-13 | 2018-05-23 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
| US20150297606A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic Lactams for Use in the Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| WO2016040858A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| WO2016183116A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
| WO2016183120A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| MX389753B (es) * | 2015-06-17 | 2025-03-20 | Pfizer | Compuestos triciclicos y su uso como inhibidores de la fosfodiesterasa |
| US11866409B2 (en) | 2015-11-02 | 2024-01-09 | Carmel-Haifa University Economic Corporation Ltd. | Apoptosis related protein in the tgf-beta signaling pathway (ARTS) mimetic compounds, compositions, methods and uses thereof in induction of differentiation and/or apoptosis of premalignant and malignant cells, thereby restoring their normal-like phenotype |
| GB201521059D0 (en) | 2015-11-30 | 2016-01-13 | Isis Innovation | Inhibitors of metallo-beta-lactamases |
| EP3565558B1 (en) | 2017-01-06 | 2023-12-06 | G1 Therapeutics, Inc. | Combination therapy with a serd compound and a cdk4/6 inhibitor for the treatment of cancer |
| WO2019006393A1 (en) | 2017-06-29 | 2019-01-03 | G1 Therapeutics, Inc. | Morphic forms of git38 and methods of manufacture thereof |
| KR20210049847A (ko) | 2018-08-24 | 2021-05-06 | 쥐원 쎄라퓨틱스, 인크. | 1,4-디아자스피로[5.5]운데칸-3-온의 개선된 합성 |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| UY39579A (es) | 2020-12-22 | 2022-07-29 | Novartis Ag | COMPUESTOS Y COMPOSICIÓN PARA EL TRATAMIENTO DE CONDICIONES ASOCIADAS CON cGAS |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US105140A (en) * | 1870-07-05 | Improvement in cigar-wrapping machines | ||
| DE2005845A1 (de) * | 1969-02-12 | 1970-09-03 | Sumitomo Chemical Company, Ltd., Osaka (Japan) | Verfahren zur Herstellung von Benzodiazepinen und ihren Salzen |
| CA1012147A (en) * | 1972-09-25 | 1977-06-14 | Hoffmann-La Roche Limited | Indolo quinoline derivatives |
| AR205437A1 (es) * | 1972-09-25 | 1976-05-07 | Hoffmann La Roche | Procedimiento para la preparacion de derivados de indoloquinolinona |
| US4225711A (en) * | 1978-10-02 | 1980-09-30 | Schering Corporation | Substituted 2-[(methylsulfinyl)acetyl]-3-heterocyclicindoles and their use as immunosuppressants |
| CA2038925A1 (en) * | 1990-03-26 | 1991-09-27 | Takashi Sohda | Indole derivatives, their production and use |
| JPH04211651A (ja) * | 1990-03-26 | 1992-08-03 | Takeda Chem Ind Ltd | 骨吸収抑制剤およびインドール誘導体 |
| GB9319100D0 (en) * | 1993-09-15 | 1993-11-03 | Pfizer Ltd | 3-(3-pyridinyl)h-indoles |
| JP2001122855A (ja) * | 1999-10-27 | 2001-05-08 | Japan Tobacco Inc | インドール化合物及びその医薬用途 |
| US6323228B1 (en) * | 2000-09-15 | 2001-11-27 | Abbott Laboratories | 3-substituted indole angiogenesis inhibitors |
| US20020128292A1 (en) * | 2000-12-07 | 2002-09-12 | Cai Sui Xiong | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| AU2002302248B2 (en) * | 2001-05-23 | 2008-03-06 | Merck Frosst Canada Ltd. | Dihydropyrrolo[1,2-A]indole and tetrahydropyrido[1,2-A]-indole derivatives as prostaglandin D2 receptor antagonists |
| DE10155076A1 (de) * | 2001-11-09 | 2003-05-22 | Merck Patent Gmbh | Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen |
| US7268159B2 (en) * | 2003-09-25 | 2007-09-11 | Wyeth | Substituted indoles |
-
2004
- 2004-04-30 IT IT000874A patent/ITMI20040874A1/it unknown
-
2005
- 2005-04-27 WO PCT/EP2005/051908 patent/WO2005105213A2/en not_active Ceased
- 2005-04-27 AU AU2005237788A patent/AU2005237788A1/en not_active Abandoned
- 2005-04-27 US US11/579,237 patent/US20070248672A1/en not_active Abandoned
- 2005-04-27 EP EP05743013A patent/EP1750687A2/en not_active Withdrawn
- 2005-04-27 JP JP2007510035A patent/JP2007535520A/ja active Pending
- 2005-04-27 CA CA002564249A patent/CA2564249A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007535520A5 (enExample) | ||
| RU2406725C2 (ru) | Соединения и композиции как ингибиторы протеинкиназы | |
| AU2014227807B2 (en) | Pharmaceutical composition comprising an AMPK activator and a serotonergic agent and methods of use thereof | |
| CA2052884C (en) | Angiotensin 11 antagonists in the treatment of hyperuricemia | |
| RU2223116C2 (ru) | Применение производных арил (или гетероарил) азолилкарбинолов в приготовлении лекарственного средства для лечения нарушений, опосредованных избытком вещества p | |
| US12233071B2 (en) | Medicament for treating cough | |
| CN107864625B (zh) | 含有取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合产品 | |
| BR112021003467A2 (pt) | composições de inibidores de cxcr4 e métodos de preparação e uso | |
| JP2012520867A5 (enExample) | ||
| RU2005120770A (ru) | Производные индазола, как антагонисты крф | |
| JP2019518765A5 (enExample) | ||
| RU2001106644A (ru) | Применение производных арил (или гетероарил) азолилкарбинолов в приготовлении лекарственного средства для лечения нарушений, опосредованных избытком вещества p | |
| RU2008120850A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
| HUP0301346A2 (hu) | Szterotonin agonista (5HT2) és antagonista (5HT6) új kombinációja gyógyászati készítményként és eljárás az előállítására | |
| WO2007120690A2 (en) | Combination histamine h1r and h4r antagonist therapy for treating pruritus | |
| TW200904430A (en) | Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye | |
| WO2023100134A1 (en) | Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer | |
| CN118201615A (zh) | 喹唑啉酮化合物用于治疗癌症的新用途 | |
| RU2007106933A (ru) | Ингибиторы hsp90 | |
| WO2012002583A1 (en) | Method for treating schizophrenia and related diseases with a combination therapy | |
| US20210369724A1 (en) | Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds | |
| WO2024209717A1 (ja) | 腫瘍治療用医薬組成物 | |
| MX2008001971A (es) | Combinacion de compuestos organicos. | |
| JP5936821B2 (ja) | チロシンキナーゼ型受容体ｋｉｔによって媒介される増殖性疾患のイマチニブによる処置を最適化する方法 | |
| RU2008118904A (ru) | Производные индола как ингибиторы н3-рецептора гистамина для лечения когнитивных расстройств и нарушений сна, ожирения и других расстройств центральной нервной системы |